Metabolism and Excretion of [14C]CC-90001 in Healthy Male Subjects
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2021-06-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 8
- Registration Number
- NCT04655898
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc, Madison, Wisconsin, United States
Expanded Access for Marizomib
- Conditions
- Solid Tumor
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Celgene
- Registration Number
- NCT04644107
- Locations
- 🇺🇸
Bristol Myers Squibb, Summit, New Jersey, United States
A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Celgene
- Target Recruit Count
- 26
- Registration Number
- NCT04639115
- Locations
- 🇺🇸
The Texas Liver Institute, San Antonio, Texas, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center OCRC, Orlando, Florida, United States
A Study of CC-90011 and Comparators in Participants With Prostate Cancer
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Celgene
- Target Recruit Count
- 6
- Registration Number
- NCT04628988
- Locations
- 🇺🇸
Local Institution - 101, New York, New York, United States
Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)
- Conditions
- Lymphoma Nonhodgkin
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Celgene
- Target Recruit Count
- 110
- Registration Number
- NCT04618081
- Locations
- 🇯🇵
Local Institution, Japan, Japan
Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Celgene
- Target Recruit Count
- 40
- Registration Number
- NCT04573582
- Locations
- 🇺🇸
Local Institution - 002, Miami, Florida, United States
🇺🇸Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville, Knoxville, Tennessee, United States
🇺🇸Local Institution - 003, Orlando, Florida, United States
A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2021-11-29
- Lead Sponsor
- Celgene
- Target Recruit Count
- 8
- Registration Number
- NCT04560738
- Locations
- 🇺🇸
Covance Clinical Research Unit Inc, Madison, Wisconsin, United States
A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 56
- Registration Number
- NCT04528290
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 30
- Registration Number
- NCT04477850
- Locations
- 🇯🇵
Local Institution - 203, Nagasaki-shi, Nagasaki, Japan
🇨🇳Local Institution - 105, Guangzhou, China
🇨🇳Local Institution - 103, Guangzhou, China
A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Celgene
- Target Recruit Count
- 62
- Registration Number
- NCT04464798
- Locations
- 🇫🇷
Local Institution - 205, Pessac, France
🇰🇷Local Institution - 501, Seoul, Korea, Republic of
🇺🇸Local Institution - 105, Lake Mary, Florida, United States